

業績目録（令和3年）

大学院科目名 血液内科学

(A-a) 英文著書
該当なし

(A-b) 和文著書
該当なし

(B-a) 英文総説
該当なし

(B-b) 和文総説

- 1 古林 勉、黒田純也. 濾胞性リンパ腫の病態・診断・治療 ～低悪性度 B 細胞リンパ腫の代表的病型として～ 日本内科学会雑誌 110: 1411-1417, 2021
- 2 志村勇司、黒田純也. 多発性骨髄腫における骨髄由来免疫抑制細胞の誘導. 臨床免疫・アレルギー科 75: 644-649, 2021.
- 3 黒田純也、志村勇司. 多発性骨髄腫治療の展望 -イサツキシマブの登場を踏まえて-. Progress in Medicine 41: 263-267, 2021
- 4 水原健太郎、黒田純也. 多発性骨髄腫における免疫調整薬の役割. 血液内科 82: 188-193, 2021.

(C-a) 英文原著

- 1 Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S, Inokuchi K, Fukushima T, Yoshida C, Uoshima N, Kiguchi T, Mita M, Aoki J, Kimura S, Karimata K, Usuki K, Shimono J, Chinen Y, Kuroda J, Matsuda Y, Nakao K, Ono T, Fujimaki K, Shibayama H, Mizumoto C, Takeoka T, Io K, Kondo T, Miura M, Minami Y, Ikezoe T, Imagawa J, Takamori A, Kawaguchi A, Sakamoto J, Kimura S. Very low-dose dasatinib in elderly chronic myeloid leukaemia patients (DAVLEC study): a single-arm, multicentre, phase 2

- trial. *Lancet Haematol* 8: e902–e911, 2021. (IF 30.153)
- 2 Nakaya A, Shibayama H, Nakatani E, Shimura Y, Kosugi S, Tanaka H, Fuchida S, Kanda J, Uoshima N, Kaneko H, Imada K, Ohta K, Ito T, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S. Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum. *eJHaem* 2: 765–773, 2021. (IF 2.997)
 - 3 Okamoto H, Uoshima N, Muramatsu A, Isa R, Fujino T, Matsumura-Kimoto Y, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, Kawata E, Uchiyama H, Kuroda J, Kyoto Clinical Hematology Study Group investigators* Combination of bone marrow biopsy and flow cytometric analysis: The prognostically relevant central approach for detecting bone marrow invasion in diffuse large B-cell lymphoma. *Diagnostics* 11: 1724, 2021. (IF 3.24)
 - 4 Nagata H, Kuriyama K, Nishikawa R, Ohshiro M, Yamamoto-Sugitani M, Fujimoto-Hirakawa Y, Matsumoto Y, Iwai T, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, Fukuda W, Uchiyama H, Kuroda J. Igaratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder. *Ann Hematol* 100: 2849–2850, 2021. (IF 3.673)
 - 5 Hosono N, Yokoyama H, Aotsuka N, Ando K, Iida H, Ishikawa T, Usuki K, Onozawa M, Kizaki M, Kubo K, Kuroda J, Kobayashi Y, Shimizu T, Chiba S, Nara M, Hata T, Hidaka M, Fujiwara SI, Maeda Y, Morita Y, Kusano M, Lu Q, Miyawaki S, Berrak E, Hasabou N, Naoe T. Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia. *Int J Clin Oncol*: 26: 2131–2141, 2021. (IF 3.850)
 - 6 Yamauchi T, Yoshida C, Usuki K, Takada S, Matsumura I, Dobashi N, Miyazaki Y, Miyamoto T, Iida H, Asou N, Kuroda J, Ichikawa S, Komatsu N, Mendes W, Honda H, Okubo S, Kurokawa M, Jiang Q, Wei A, Ishizawa K. Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy. *Jpn J Clin Oncol* 51: 1372–1382, 2021. (IF 3.019)
 - 7 Yamashita T, Takamatsu H, Kawamura K, Sunami K, Hagiwara S, Epid

- GDC, Itagaki M, MD, Takahashi T, Kondo K, Ikeda T, Watanabe-Inamoto K, Handa H, Imaizumi Y, Kuroda J, Murakami J, Nakamura Y, Nakazawa H, Ozaki S, Ohkura M, Takeuchi M, MD, Nagai H, Hanamura I, Nakao S, Tobinai K, Iida S. A nationwide survey on central nervous system multiple myeloma in Japan: Analysis of prognostic factors that improve survival. *Br J Haematol* 195: 217-229, 2021. (IF 6.998)
- 8 Izutsu K, Ando K, Nishikori M, Shibayama H, Teshima T, Kuroda J, Kato K, Imaizumi Y, Nosaka K, Sakai R, Hojo S, Nakanishi T, Rai S. Phase 2 Study of Tazemetostat for Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma with EZH2 Mutation in Japan. *Cancer Sci* 112: 3627-3635, 2021. (IF 6.716)
- 9 Kawaji-Kanayama Y, Kobayashi T, Muramatsu A, Uchiyama H, Sasaki N, Uoshima N, Nakao M, Takahashi R, Shimura K, Kaneko H, Kiyota M, Wada K, Chinen Y, Hirakawa K, Fuchida S, Shimazaki C, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Shimura Y, Horiike S, Taniwaki M, Kuroda J, Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients. *Cancer Reports*: e1476, 2021. (IF 0.768)
- 10 Hosen N, Yoshihara S, Takamatsu H, Ri M, Nagata Y, Kosugi H, Shimomura Y, Hanamura I, Fuji S, Minauchi K, Kuroda J, Suzuki R, Nishimura N, Uoshima N, Nakamae H, Kawano Y, Mizuno I, Gomyo H, Suzuki K, Ozaki S, Nakamura S, Imai Y, Kizaki M, Negoro E, Handa H, Iida S. Expression of activated integrin $\beta 7$ in multiple myeloma patients. *Int J Hematol* 114; 3-7, 2021. (IF 2.49)
- 11 Katsuragawa-Taminishi Y, Ide D, Maegawa-Matsui S, Fuchida S, Hatsuse M, Murakami S, Kuroda J, Shimazaki C. Acquired Amegakaryocytic Thrombocytopenic Purpura that Presented as Cyclic Thrombocytopenia Associated with Anti-Phospholipid Antibody Syndrome. *Clin Hematol Res* 4: 42-46, 2021. (IF なし)
- 12 Terui Y, Rai S, Izutsu K, Yamaguchi M, Takizawa J, Kuroda J, Ishikawa T, Kato K, Suehiro Y, Fukuhara N, Ohmine K, Goto H,

- Yamamoto K, Kanemura N, Ueda Y, Ishizawa K, Kumagai K, Kawasaki A, Saito T, Hashizume M, Shibayama H. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. *Cancer Sci* 112: 2845–2854, 2021. (IF 6.716)
- 13 Okamoto H, Kamitsuji Y, Komori Y, Sasaki N, Tsutsumi Y, Miyashita A, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, Uoshima N, Kuroda J. Durable remission of chemotherapy-refractory myeloid sarcoma by azacitidine. *Tohoku J Exp Med* 254; 101–105, 2021. (IF 2.547)
- 14 Matsumoto Y, Tsukamoto T, Chinen Y, Shimura Y, Sasaki N, Nagoshi H, Sato R, Adachi H, Nakano M, Horiike S, Kuroda J, Taki T, Tashiro K, Taniwaki M. Detection of novel and recurrent conjoined genes in non-Hodgkin B-cell lymphoma. *J Clin Exp Hematop* 61: 71–77, 2021. (IF なし)
- 15 Kawai H, Ando K, Maruyama D, Yamamoto K, Kiyohara E, Terui Y, Fukuhara N, Miyagaki T, Tokura Y, Sakata-Yanagimoto M, Igarashi T, Kuroda J, Fujita J, Uchida T, Ishikawa T, Yonekura K, Kato K, Nakanishi T, Nakai K, Matsunaga R, Tobinai K. Phase 2 study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. *Cancer Sci* 112; 2426–2435, 2021. (IF 6.716)
- 16 Matsumoto M, Suzuki K, Kuroda J, Taniwaki M, Sunami K, Kosugi H, Ando K, Maruyama D, Tobinai K, Kher U, Farooqui M, Liao J, Marinello P, Matsuda K, Koh Y, Shimamoto T, Iida S. Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients. *Int J Hematol* 113; 777–784, 2021. (IF 2.49)
- 17 Takakuwa T, Ohta K, Nakatani E, Ito T, Kaneko H, Fuchida S, Shimura Y, Yagi H, Shibayama H, Kanda J, Uchiyama H, Kosugi S, Tanaka H, Kawata E, Uoshima N, Ishikawa J, Shibano M, Karasuno T, Shindo M, Shimizu Y, Imada K, Kanakura Y, Kuroda J, Hino M, Nomura S, Takaori-Kondo A, Shimazaki C, Matsumura I. Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma. *Hematol Oncol* 39: 349–357, 2021. (IF 5.271)

- 18 Takakuwa T, Yamamura R, Ohta K, Kaneko H, Imada K, Nakaya A, Fuchida S, Shibayama H, Matsuda M, Shimazu Y, Adachi Y, Kosugi S, Uchiyama H, Tanaka H, Hanamoto H, Shimura Y, Kanda J, Onda Y, Uoshima N, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S. Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis. *Eur J Haematol* 106: 555-562, 2021. (IF 3.674)
- 19 Okamoto H, Uoshima N, Kamitsuji Y, Kawata E, Komori Y, Sasaki N, Tsutsumi Y, Tsukamoto T, Mizutani S, Nannya Y, Kuroda J. Paroxysmal Nocturnal Hemoglobinuria Complicated with Essential Thrombocythemia Harboring Concomitant PIGA, CALR, And ASXL1 Mutations. *Ann Hematol* 100: 2113-2115, 2021. (IF 3.673)
- 20 Ohmachi K, Kinoshita T, Tobinai K, Ogawa G, Mizutani T, Yamauchi N, Fukuhara N, Uchida T, Yamamoto K, Miyazaki K, Tsukamoto N, Iida S, Utsumi T, Yoshida I, Imaizumi Y, Tokunaga T, Yoshida S, Masaki Y, Murayama T, Yakushijin Y, Suehiro Y, Nosaka K, Dobashi N, Kuroda J, Takamatsu Y, Maruyama D, Ando K, Ishizawa K, Ogura M, Yoshino T, Hotta T, Tsukasaki K, Nagai H. A randomized phase II/III study of R-CHOP versus CHOP combined with dose-dense rituximab for DLBCL: JCOG0601. *Blood Adv* 5: 984-993, 2021. (IF 7.637)
- 21 Yasuda T, Takagi T, Asai J, Katoh N, Kuroda J, Kuwahara Y, Morinaga Y, Konishi E, Uchiyama K, Naito Y, Itoh Y. Mycosis fungoides in a patient with ulcerative colitis on anti-tumor necrosis factor-alpha therapy. *Clin J Gastroenterol* 14: 170-175, 2021. (IF 1.375)
- 22 Nishiyama D, Chinen Y, Isa R, Fujibayashi Y, Kuwahara-Ota S, Yamaguchi J, Takimoto-Shimomura T, Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Handa H, Kuroda J. EWSR1 overexpression is a pro-oncogenic event in multiple myeloma. *Int J Hematol* 113: 381-394, 2021. (IF 2.49)
- 23 Maruyama D, Iida S, Ogawa G, Kusumoto S, Fukuhara S, Fukuhara N, Seo S, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Hangaishi A, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Minauchi K, Ohtsuka E, Hanamura I, Tokunaga T, Yoshida

S, Yamasaki S, Suehiro Y, Kamiyama Y, Miyamoto K, Watanabe Y, Tobinai K, Tsukasaki K, Nagai H. Randomized phase II study to optimize melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105). Br J Haematol 192: 531-541, 2021. (IF 8.615)

- 24 Kanai R, Miyagawa-Hayashino A, Shishido-Hara Y, Nakamura N, Omatsu I, Morinaga Y, Shimura Y, Kuroda J, Itoh K, Konishi E. Mantle cell lymphoma with EBV-positive Hodgkin and Reed-Sternberg-like cells in a patient after autologous PBSCT: Phenotypically distinct but genetically related tumors. Pathol Int 71: 96-101, 2021. (IF 2.121)

(C-b) 和文原著
該当なし

(D) 学会発表

I) 特別講演、教育講演等

- 1 黒田純也. 教育講演 日常診療と形質細胞性腫瘍. 日本内科学会近畿地方会生涯教育講演, 2021, 大阪.

II) シンポジウム、ワークショップ、パネルディスカッション等

- 1 黒田純也. 多発性骨髄腫における分子腫瘍学的多様性の克服に向けて. 千里ライフサイエンスセミナーS3 シンポジウム「ライフステージとがん、細胞老化の関与とその治療標的としての可能性」, 2021, 大阪
- 2 水谷信介、太田沙絵子、金山悠加、村松彩子、岡本明也、大西朗生、水原健太郎、民西葉子、山口順子、伊佐怜子、藤野貴大、西山大地、木元弥生、塚本 拓、志村勇司、古林 勉、志村和穂、高橋良一、兼子裕人、黒田純也. プレナリー. Carfilzomib 含有救援療法後に2回目の自家末梢血幹細胞移植を実施した再発多発性骨髄腫の検討. 第46回日本骨髄腫学会学術集会, 2021, 福島

III) 国際学会における一般発表

- 1 Kumagai T, Murai K, Ureshino H, Tanaka H, Nishiwaki K, Wakita S, Inokuchi K, Fukushima T, Yoshida C, Mita M, Uoshima N, Kiguchi T, Aoki J, Kimura S, Karimata K, Usuki K, Shimono J, Chinen Y,

- Kuroda J, Matsuda Y, Nakao K, Ono T, Fujimaki K, Shibayama H, Mizumoto C, Takeoka T, Io K, Kondo T, Miura M, Minami Y, Ikezoe T, Imagawa J, Takamori A, Kawaguchi A, Sakamoto J, Kimura S. Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial. The American Society of Hematology 63rd Annual Meeting and Exposition. 2021 Dec 11-14, USA
- 2 Fukushima K, Shibayama H, Chi SG, Hosono N, Yamauchi T, Katagiri S, Gotoh A, Eguchi M, Morishita T, Ogasawara R, Kondo T, Yanada M, Yamamoto K, Kobayashi T, Kuroda J, Kamoda Y, Usuki K, Utsu Y, Aotsuka N, Yoshimitsu M, Ishitsuka K, Ono T, Takahashi N, Iyama S, Nakamura M, Nakamura Y, Fukuhara S, Izutsu K, Yamauchi N, Yuda J, Minami Y. Clinical Significance of *FLT3* Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01. The American Society of Hematology 63rd Annual Meeting and Exposition. 2021 Dec 11-14, USA
- 3 Makita S, Kusumoto S, Miyagi-Maeshima A, Hashimoto H, Tsujimura H, Uchida T, Inoue H, Ohtsuka E, Kurosawa M, Takayama N, Negoro E, Suzuki Y, Kuroda J, Murayama K, Takahashi N, Shimada K, Okamoto M, Makita M, Iwasaki H, Yoshida M, Asano N, Tamaru J, Maruyama D, Yamaguchi M, Nagai H. Clinical Outcomes of Elderly Patients with Advanced-Stage Classic Hodgkin Lymphoma Who Received an ABVD Regimen: A Multi-Center Retrospective Study in Japan (HORIZON study). The American Society of Hematology 63rd Annual Meeting and Exposition. 2021 Dec 11-14, USA
- 4 Hosono N, Yamauchi T, Chi SG, Fukushima K, Shibayama H, Katagiri S, Gotoh A, Eguchi M, Morishita T, Ogasawara R, Kondo T, Yanada M, Yamamoto K, Kobayashi T, Kuroda J, Usuki K, Utsu Y, Aotsuka N, Yoshimitsu M, Ishitsuka K, Ono T, Takahashi N, Iyama S, Nakamura M, Nakamura Y, Fukuhara S, Izutsu K, Yamauchi N, Yuda J, Minami Y. Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia. The American Society of Hematology 63rd Annual Meeting and Exposition. 2021 Dec 11-14, USA

- 5 Uchiyama S, Hirotsuka N, Chi SG, Fukushima K, Shibayama H, Hosono N, Yamauchi T, Katagiri S, Gotoh A, Eguchi M, Morishita T, Ogasawara R, Kondo T, Yanada M, Yamamoto K, Kobayashi T, Kuroda J, Usuki K, Aotsuka N, Yoshimitsu M, Ishitsuka K, Ono T, Takahashi N, Iyama S, Nakamura M, Nakamura Y, Fukuhara S, Izutsu K, Yamauchi N, Yuda J, Minami Y. Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis. The American Society of Hematology 63rd Annual Meeting and Exposition. 2021 Dec 11-14, USA
- 6 Chi SG, Fukushima K, Shibayama H, Hosono N, Yamauchi T, Katagiri S, Gotoh A, Eguchi M, Morishita T, Ogasawara R, Kondo T, Yanada M, Yamamoto K, Kobayashi T, Kuroda J, Kamoda Y, Usuki K, Utsu Y, Aotsuka N, Yoshimitsu M, Ishitsuka K, Nagata Y, Ono T, Fujishima N, Takahashi N, Horiguchi H, Iyama S, Nakamura M, Kojima K, Yamamoto K, Nakamura Y, Fukuhara S, Izutsu K, Yamauchi N, Yuda J, Minami Y. Genomic Analysis of *NPM1* Mutation and *KMT2A(MLL)*-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01. The American Society of Hematology 63rd Annual Meeting and Exposition. 2021 Dec 11-14, USA
- 7 Katagiri S, Akahane D, Gotoh S, Chi SG, Fukushima K, Shibayama H, Hosono N, Yamauchi T, Eguchi M, Morishita T, Ogasawara R, Kondo T, Yanada M, Yamamoto K, Kobayashi T, Kuroda J, Usuki K, Utsu Y, Aotsuka N, Yoshimitsu M, Ishitsuka K, Ono T, Takahashi N, Iyama S, Nakamura M, Nakamura Y, Izutsu K, Yamauchi N, Yuda J, Minami Y. Genomic Analysis Focusing on *RUNX1-RUNX1T1* in Japanese Patients with AML: HM-Screen-Japan 01. The American Society of Hematology 63rd Annual Meeting and Exposition. 2021 Dec 11-14, USA
- 8 Rai S, Ando K, Takaori-Kondo A, Shibayama H, Teshima T, Kuroda J, Kato K, Imaizumi Y, Nosaka K, Sakai R, Nakanishi T, Hojo S, Izutsu K. Phase 2 study of tazemetostat in Japanese patients with relapsed or refractory EZH2 mutation-positive B-cell Non-Hodgkin's Lymphoma. American Association for Cancer Research Annual Meeting 2021. 2021 Apr 10-15, Philadelphia, USA

E 研究助成（競争的研究助成金）

総額 887 万円

公的助成

代表（総額）・小計 533 万円

- 1 黒田純也：文部科学省科学研究費補助金基盤研究（C）平成 31-令和 3 年
多発性骨髄腫に対する RSK2 標的化創薬研究 助成金額 100 万円
- 2 水谷信介．文部科学省科学研究費補助金若手研究 令和 3-4 年度
普遍的成熟 B 細胞腫瘍モデル細胞の網羅的遺伝子編集による高悪性度病態
形成機序の解明 助成金額 180 万円
- 3 水谷信介．文部科学省科学研究費補助金 2020 年度研究活動スタート支援
令和 2-3 年度
網羅的ゲノム編集生体内スクリーニング法による難治性 B 細胞リンパ腫治
療標的の探索 助成金額 110 万円
- 4 塚本 拓．文部科学省科学研究費補助金若手研究 令和 3-5 年度
Galectin-9 を介したマントル細胞リンパ腫の BCR シグナル活性化機序の
解明 助成金額 143 万円

分担・小計 224 万円

- 1 黒田純也 AMED 革新的がん医療実用化研究事業． 令和 3-6 年度
高齢者多発性骨髄腫に対する標準治療の確立と治療効果・耐性獲得に関わ
る分子基盤の探索 助成金額 70 万円
- 2 黒田純也 AMED 臨床研究・治験推進研究事業． 令和 2-5 年度
急性骨髄性白血病に対する治療用がんペプチドワクチン「DSP-7888」の
Phase2 医師主導治験 助成金額 154 万円

財団等からの助成・小計 130 万円

- 1 志村勇司 一般社団法人 日本血液学会研究助成 2021 年度
多発性骨髄腫における腫瘍由来エクソソームの解析および新規治療戦略
開発 助成金額 30 万円
- 2 志村勇司 一般財団法人京都予防医学センター がん研究助成制度
京都府立医科大学における造血器腫瘍に対するキメラ抗原受容体 T 細胞療
法(CAR-T)の患者レジストリ・バイオバンク構築事業 助成金額 20 万円
- 3 水谷信介 2021 年度日本骨髄腫学会奨励賞
PDPK1-RSK2 シグナル恒常的活性化新規多発性骨髄腫疾患モデル細胞を用

- いた病態形成メカニズムの解明 助成金額 50 万円
- 4 水谷信介 2021 年度 ENT M Dr. 浅野登&暉子基金医学基礎研究助成事業奨励金受賞 助成金額 30 万円